All‐cause mortality · pulmonary arterial hypertension
Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in mortality compared with placebo, on combination therapy (moderate certainty).
1 finding from 1 review
All‐cause mortality · pulmonary arterial hypertension
Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in mortality compared with ERA (moderate certainty).
1 finding from 1 review
All‐cause mortality · pulmonary arterial hypertension
Group 1 Pulmonary arterial hypertension ‐ PDE5i leads to lower mortality compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality · people with pulmonary hypertension group 2 ‐ 4
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with pulmonary hypertension due to lung disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with pulmonary hypertension due to left‐heart disease
Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Mortality ‐ sildenafil versus placebo · people with pulmonary hypertension due to CTEPH
1 finding from 1 review
Mortality ‐ sildenafil versus bosentan · people with pulmonary hypertension due to CTEPH
Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i showed no clear difference in mortality ‐ sildenafil versus bosentan compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · pulmonary arterial hypertension
1 finding from 1 review
All‐cause mortality · pulmonary arterial hypertension
Prostacyclin probably leads to lower mortality compared with control (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality · Adults (>18 years) with pulmonary hypertension of varied aetiology (PAH, CTEPH and left heart disease)
The intervention showed no clear difference in mortality (low certainty).
1 finding from 1 review
Mortality mean duration of study 30.2 weeks · pulmonary arterial hypertension
Endothelin receptor antagonists showed no clear difference in mortality mean duration of study 30.2 weeks compared with placebo (low certainty).
1 finding from 1 review